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Abstract
Background: The administration of antiplatelet drugs before coronary artery bypass graft surgery
(CABG) is associated with an increased risk of major hemorrhage and related surgical
reexploration. Little is known about the relative effect of combined clopidogrel and aspirin on
blood product use around the time of CABG. We evaluated the associated risk between the
combined use of aspirin and clopidogrel and the transfusion of blood products perioperatively.
Methods: We retrospectively studied a cohort of 659 individuals who underwent a first CABG,
without concomitant valvular or aortic surgery, at a single large Canadian cardiac surgical centre
between January 2000 and April 2002. The four study exposure groups were those prescribed
aspirin (n = 105), clopidogrel (n = 11), the combination of both (n = 46), or neither drug (n = 497),
within 7 days prior to CABG. The primary study outcome was the excessive transfusion of blood
products during CABG and up to the second post-operative day, defined as ≥ 2 units of packed red
blood cells (PRBC), ≥ 2 units of fresh frozen plasma, ≥ 5 units of cryoprecipitate or ≥ 5 units of
platelets. Secondary outcomes included the mean number of transfused units of each type of blood
product.
Results: A greater mean number of units of PRBC were transfused among those who received
clopidogrel alone (2.9) or in combination with aspirin (2.4), compared to those on aspirin alone
(1.9) or neither antiplatelet drug (1.4) (P = 0.001). A similar trend was seen for the respective mean
number of transfused units of platelets (3.6, 3.7, 1.3 and 1.0; P < 0.001) and fresh frozen plasma
(2.5, 3.1, 2.3, 1.6; P = 0.01). Compared to non-users, the associated risk of excessive blood product
transfusion was highest among recipients of aspirin and clopidogrel together (adjusted OR 2.2, 95%
CI 1.1–4.3). No significant association was seen among lone users of aspirin (adjusted OR 1.0, 95%
CI 0.6–1.6) or clopidogrel (adjusted OR 0.7, 95% CI 0.2–2.5), compared to non-users.
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Conclusions: While combined use of aspirin and clopidogrel shortly before CABG surgery may
increase the associated risk of excess transfusion of blood products perioperatively, several study
limitations prevent any confident conclusions from being drawn. Beyond challenging these findings,
future research might focus on the value of both intraoperative monitoring of platelet function, and
the effectiveness of antifibrinolytic agents, at reducing the risk of postoperative bleeding.
Background
Antiplatelet agents are effective in the management of sta-
ble and unstable coronary artery disease [1]. Early initia-
tion of these drugs also reduces the risk of graft occlusions
after coronary artery bypass surgery (CABG) [2]. The com-
bination of clopidogrel, an adenosine diphosphate recep-
tor (ADP) antagonist, and aspirin, has been shown to
reduce the risk of cardiovascular death or nonfatal myo-
cardial infarction among individuals presenting with non-
STEMI acute coronary syndromes [3]. A similar benefit
was seen among those receiving percutaneous coronary
interventions [4].
The potent inhibition of platelet function achieved by the
combination of aspirin and clopidogrel leads to a prolon-
gation of the bleeding time [5] and an increased risk of
major hemorrhage [3], thus, raising concerns about their
safety around the time of CABG [6]. In one small study,
clopidogrel and aspirin use before CABG was associated
with more bleeding complications and blood product
transfusions [7]. In the current study, we investigated
whether recent use of aspirin, clopidogrel, or both was as-
sociated with an increased risk of blood product transfu-
sion during and soon after CABG.
Methods
We conducted a retrospective cohort study at the Hamil-
ton Health Sciences Corporation, General Division, a
large academic referral centre for patients from Southwest-
ern Ontario. The immediate postoperative care of these
patients is provided through a dedicated cardiac surgery
intensive care unit (ICU), staffed by trained intensivists
and nurses. Pericardial and pleural chest tube output is
monitored frequently within the first few hours after sur-
gery, and then hourly thereafter. Once stable, extubated
patients are transferred to a cardiac surgery step-down
unit, on at least the second postoperative day. The use of
intraoperative blood products or antifibrinolytic agents
(e.g., aprotinin) is left to the discretion of the anesthetist
and surgeon, while postoperative transfusions are usually
decided upon by the attending intensivist.
All laboratory results and blood product transfusion in-
formation are entered into the hospital's patient care com-
puter system from the respective laboratories. Using the
patient hospital identification number, information is
available about the type of blood product transfused, the
number of units and volume, and the date of transfusion.
This same computer system also contains a complete
medication history for each patient, including the drug
name, dose, and date of initiation and cessation.
We included patients who underwent their first CABG,
without concomitant valvular or aortic surgery, between
January 2000 and April 2002. A total of 1626 individuals
were identified from a regularly updated register of all
CABG recipients at our centre. A list of randomly generat-
ed numbers was created in Excel 5.0 (Microsoft Corpora-
tion), merged alongside the original list of CABG patients,
and then randomly re-sorted once more. From this new
list of 1626 randomly sorted patients we abstracted data
on 675 patients, surpassing the estimated sample size, as
outlined below. Of these 675 individuals, the identifica-
tion numbers of 7 did not match with those in the patient
care computer system, while another 9 did not undergo
isolated CABG surgery. Thus, a total of 659 patients were
included herein.
The four study exposure groups were divided into those
prescribed i) aspirin, ii) clopidogrel, iii) both drugs or iv)
neither drug, each ≤ 7 days before CABG. The primary
study outcome was the transfusion of an excessive
number of blood products during, and up to, the second
post-CABG day. The latter was defined as ≥ 2 units of non-
autologous packed red blood cells (PRBC), ≥ 2 units of
fresh frozen plasma (FFP), ≥ 5 units of cryoprecipitate, or
≥ 5 units of platelets – quantities that are both clinically
important and financially costly [8,9]. Other secondary
outcomes included: i) the transfusion of any quantity of
blood products up to the second post-CABG day; ii) the
mean number of transfused units of each type of blood
product, up to the second post-operative day; iii) the
mean number of transfused units of FFP or cryoprecipi-
tate; and iv) the mean number of transfused units of FFP,
cryoprecipitate or platelets, together a reflection of a pa-
tient's perceived or actual bleeding tendency.
This study was solely designed to examine blood product
use among a large sample of patients. Accordingly, we
used the hospital computer system as the single source of
all study data; no information was obtained about preop-
erative renal function, post-operative chest tube drainage,
hemodynamics, hematological indices, or the need for
surgical reexploration. Whether the surgery was urgent orBMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/3
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elective was not recorded, nor were other patient charac-
teristics, including comorbidity factors.
Statistical analysis
We expressed the risk of excessive transfusion in relation
to antiplatelet drug use (i.e., no drug, aspirin, clopidogrel
or both), using unadjusted and adjusted odds ratios (OR)
and a 95% confidence interval (CI). With logistic regres-
sion analysis, we adjusted for participant age, sex and re-
ceipt of any autologous whole blood within 2 days
following surgery. Patient characteristics and study out-
comes were compared between the four drug exposure
groups using ANOVA for continuous variables, and a chi-
square test for categorical data. The study sample size was
estimated assuming that, for each person receiving com-
bined aspirin and clopidogrel, at least 6 patients would re-
ceive neither drug. Expecting that 50% of non-users and
70% of combined users might receive an excessive
amount of blood products [7], and setting α = 0.05 and β
= 0.20, we estimated that approximately 50 combined us-
ers and 325 non-users would be needed.
Statistical significance was set at a 2-sided P-value of 0.05,
and all analyses were performed using SAS Version 8.0
(SAS Institute Inc., Cary, North Carolina). The Hamilton
Health Sciences Corporation Research Ethics Board grant-
ed permission to conduct this audit study.
Results
A total of 105 individuals (16.0%) received aspirin alone,
11 (1.7%) received clopidogrel alone, 46 (7.0%) received
aspirin and clopidogrel, while the remaining 497 patients
(75%) did not receive an antiplatelet drug before surgery
(Table 1). Neither the mean age nor preoperative hemo-
globin concentration was significantly different between
groups, but there were more women prescribed clopidog-
rel. Those not prescribed an antiplatelet drug were more
likely to have received autologous whole blood (P = 0.01)
(Table 1).
Individuals prescribed either clopidogrel, or clopidogrel
plus aspirin, were transfused more blood products during
and early after surgery, compared to those prescribed nei-
ther (Table 2). On average, 2.9 units of PRBC were given
to clopidogrel users, 2.4 units to combined users, and
only 1.4 units to non-users (P = 0.001). Those prescribed
clopidogrel (3.6 units) or clopidogrel plus aspirin (3.7
units) received more platelets than those prescribed aspi-
rin (1.3 units) or neither drug (1.0 units) (Table 2). Clopi-
dogrel users, either alone (8.0 units), or in combination
with aspirin (7.5 units), received almost twice the total
number of units of FFP, cryoprecipitate and platelets, than
those on aspirin (4.2 units) or neither drug (3.3 units) (P
= 0.006) (Table 2).
Compared to non-users, the risk of excessive blood prod-
uct transfusion was highest among recipients of combined
aspirin and clopidogrel (crude OR 2.3, 95% CI 1.2–4.5),
an effect that persisted after adjustment for a few potential
confounders (adjusted OR 2.2, 95% CI 1.1–4.3). No in-
creased risk was seen among users of aspirin (adjusted OR
1.0, 95% CI 0.6–1.6) or clopidogrel alone (adjusted OR
0.7, 95% CI 0.2–2.5) (Table 3). Similarly, compared to
non-users, those recently prescribed combined aspirin
and clopidogrel were more likely to receive 1 or more
units of any type of blood product (crude OR 2.4, 95% CI
1.2–4.9). This risk estimate was further attenuated after
adjusting for age, sex and autologous whole blood use
(adjusted OR 2.1, 95% CI 1.0–4.5) (Table 3).
Discussion
In a cohort of 659 CABG patients, we observed an in-
creased total volume and associated risk of blood product
transfusion among those recently prescribed preoperative
clopidogrel in combination with aspirin.
We did not obtain information about patient comorbidi-
ties (e.g., recent myocardial infarction), whether the
CABG was elective or emergent [10], or about the use of
preoperative anticoagulants or thrombolytic drugs [11].
Unstable patients undergoing emergency CABG might be
expected to receive dual antiplatelet therapy at higher
rates than elective cases, and because they often require
more intense perioperative support and monitoring [10],
urgent cases might also receive more blood products. The
relationship between dual antiplatelet drug use and peri-
Table 1: Characteristics of 659 coronary artery bypass graft surgery patients, according to antiplatelet drug prescription before surgery
Characteristic None (n = 497) Aspirin (n = 105) Clopidogrel 
(n = 11)
Aspirin plus clopidogrel 
(n = 46)
Statistical comparison 
between groups
Mean (SD) age, years 64.9 (10.1) 66.7 (8.8) 67.6 (6.3) 65.8 (12.2) P = 0.1
Number (%) females 105 (21.1) 34 (32.7) 6 (54.6) 14 (30.4) P = 0.004
Mean (SD) preoperative hemoglobin concentration, 
g/L
116.3 (17.4) 115.5 (19.0) 107.0 (21.6) 111.7 (17.4) P = 0.3
Number (%) who received any quantity of autologous 
whole blood during or after surgery
31 (6.2) 0 (0.0) 0 (0.0) 0 (0.0) P = 0.01
SD standard deviationBMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/3
Page 4 of 6
(page number not for citation purposes)
operative blood product use is likely confounded by sev-
eral elements, as noted by the decline in the OR for
transfusion of any blood product from 2.4 to 2.1, after ad-
justing for age, sex and autologous whole blood use (Ta-
ble 3). Since these data were derived from a patient care
database, some individuals classified as not having re-
ceived an antiplatelet drug may have actually received one
or both drugs just prior to their hospital admission for
elective CABG. Such misclassification bias usually leads to
a diminution of the observed effect size, such that we may
have underestimated the true association between dual
antiplatelet drug use and excessive blood product
transfusion.
Most surgeons and anesthetists likely knew whether their
patient had recently received an antiplatelet drug, possibly
lowering their threshold for administering blood prod-
ucts or antifibrinolytic agents to minimize bleeding. Fur-
thermore, we did not assess for other clinical indicators of
bleeding risk, such as preoperative renal function, postop-
erative chest tube output or hypotension in the ICU. Fi-
nally, because few patients received clopidogrel alone,
confident conclusions cannot be drawn about their over-
all need for blood product transfusion. In light of these
potential threats to validity, our data should be viewed as
hypothesis generating; however, they may assist in design-
ing future research studies, while raising appropriate ques-
tions about how to best minimize blood product use in
the current era of combined antiplatelet drug therapy
[3,12].
These study findings, and those of others, imply that use
of dual antiplatelet agents before CABG is associated with
increased blood product transfusion among some pa-
tients, a reflection of post-operative bleeding risk. It has
been suggested that this risk may be related to the timing
of the last administered drug dose, a point not properly
defined in our study. For example, in a prospective study
Table 2: Number of units of blood products transfused during surgery and up to the second post-operative day, according to antiplatelet 
drug prescription before coronary artery bypass graft surgery
Mean (SD) number of units transfused
Blood product(s) None (n = 497) Aspirin (n = 105) Clopidogrel (n = 11) Aspirin plus clopidogrel 
(n = 46)
Statistical comparison 
between groups
Packed red blood cells 1.4 (2.0) 1.9 (2.4) 2.9 (3.4) 2.4 (2.3) P = 0.001
Platelets 1.0 (3.7) 1.3 (3.1) 3.6 (6.0) 3.7 (5.2) P < 0.001
Fresh frozen plasma 1.6 (2.9) 2.3 (4.4) 2.5 (5.4) 3.1 (5.4) P = 0.01
Cryoprecipitate 0.6 (4.6) 0.5 (3.2) 1.8 (4.0) 0.6 (3.3) P = 0.8
Fresh frozen plasma 
and cryoprecipitate
2.3 (5.8) 2.8 (6.4) 4.4 (7.7) 3.8 (7.5) P = 0.3
Fresh frozen plasma, 
cryoprecipitate and 
platelets
3.3 (8.3) 4.2 (8.8) 8.0 (13.4) 7.5 (11.6) P = 0.006
Table 3: Rate and risk of excessive or any blood product transfusion according to antiplatelet drug prescription before coronary artery 
bypass graft surgery
Outcome Antiplatelet drug(s) 
prescribed
No. (%) with outcome Crude OR (95% CI) Adjusted OR (95% CI)**
Excessive transfusion* Neither 260 (52.4) 1.0 1.0
Aspirin alone 58 (55.8) 1.1 (0.8–1.8) 1.0 (0.6–1.6)
Clopidogrel alone 6 (54.6) 1.1 (0.3–3.6) 0.7 (0.2–2.5)
Aspirin and clopidogrel 33 (71.7) 2.3 (1.2–4.5) 2.2 (1.1–4.3)
Any transfusion Neither 300 (60.5) 1.0 1.0
Aspirin alone 70 (66.7) 1.3 (0.8–2.0) 1.1 (0.7–1.7)
Clopidogrel alone 9 (81.8) 3.0 (0.6–13.8) 1.8 (0.4–9.2)
Aspirin and clopidogrel 36 (78.3) 2.4 (1.2–4.9) 2.1 (1.0–4.5)
* Defined as a transfusion of ≥ 2 units of non-autologous packed red blood cells, ≥ 2 units of fresh frozen plasma, ≥ 5 units of cryoprecipitate, or ≥ 
5 units of platelets, during CABG and up to the second post-operative day. ** Adjusted for age, sex and receipt of 1 or more units of autologous 
whole blood perioperatively. OR odds ratio; CI confidence intervalBMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/3
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of 100 CABG patients, those who received aspirin within
2 days of surgery had greater impairment of platelet func-
tion than participants who stopped their aspirin 3 to 7
days preoperatively [13]. A similar dose-dependent effect
on bleeding time and ex vivo ADP-induced platelet aggre-
gation has also been observed for clopidogrel [14].
In the CURE trial, 12,562 patients presenting with non-
STEMI acute coronary syndromes were randomized to re-
ceive either aspirin plus clopidogrel or aspirin plus place-
bo [3]. Participants who required CABG, and who
received dual antiplatelet therapy within 5 days prior to
surgery, had a higher rate of major postoperative bleeding
than those assigned aspirin and placebo (9.6% vs. 6.3%;
P = 0.06) [3]. In a prospective cohort study of 247 patients
undergoing CABG, 51 individuals received preoperative
aspirin plus clopidogrel [7]. In the latter group, there was
a higher rate of reoperation for bleeding compared to
those prescribed aspirin alone (9.8% vs. 1.6%; OR 6.9,
95% CI 1.6–30). Moreover, recipients of both drugs were
transfused more units of PRBC (3 vs. 1.6; P < 0.001),
platelets (4.3 vs. 1.7; P = 0.05), FFP (1.1 vs. 0.6; P = 0.08)
and cryoprecipitate (2.4 vs. 1.2; P = 0.04) [7].
In the most recently published cohort study, among the
59 patients who received clopidogrel up to 7 days before
CABG, there was about 250 mL more of chest tube drain-
age 8 hours after surgery, compared to non-recipients
[15]. Persons administered clopidogrel also had a higher
rate of reoperation for bleeding (6.8% vs. 0.6%), and re-
ceived more units of PRBC (2.5 vs. 1.7), platelets (0.9 vs.
0.2) and FFP (0.7 vs. 0.2) [15]. Unlike those prescribed as-
pirin alone, patients taking both aspirin and clopidogrel
required a greater number of units of PRBC (2.6 vs. 1.6),
platelets (0.9 vs. 0.2) and FFP (0.8 vs. 0.3), compared to
individuals who received neither drug [15]. Together,
these data suggest that recent administration of clopidog-
rel, especially in combination with aspirin, increases the
risk of postoperative bleeding [16].
Deciding if, and when, antiplatelet agents should be held
prior to CABG may depend not only on safety issues (e.g.,
postoperative bleeding risk), but also on maintaining
graft patency [2]. After the first week of CABG, reactive
thrombocytosis is common, and may be an important risk
factor for late symptomatic vein graft occlusion [17]. In a
case-control study of the 8,641 consecutive CABG proce-
dures performed during the late 1980's and early 1990's,
preoperative aspirin use was associated with a lower risk
of in-hospital mortality, compared with drug cessation
within 7 days before surgery (adjusted OR 0.55, 95% CI
0.31–0.98). Furthermore, there was no increased risk of
major bleeding [18]. While similar data on graft patency
are not available for clopidogrel, one small randomized
double-masked placebo-controlled trial showed that initi-
ation of ticlopidine (an older ADP inhibitor) on day 2
post-CABG, and continued for another 12 months, was
associated with significantly lower rate of graft occlusion
at up to 1 year [19]. Thus, until more data are made avail-
able, it would seem both safe and sensible to withhold
clopidogrel, and perhaps, aspirin, for at least 5 days before
CABG, and then to restart one or both drugs soon after
surgery [2].
Since some individuals continue to receive dual antiplate-
let drugs up to the time of CABG, often with emergency
surgery, other methods should be considered to reduce
the risk of major postoperative bleeding, including the use
of antifibrinolytic agents. In one clinical trial, 202 CABG
patients were randomized to receive either placebo or
low-dose aprotinin, a serine protease inhibitor, at a dose
of 0.5 million kallikrein inhibiting units (KIU) twice dur-
ing surgery [20]. Aprotinin recipients required significant-
ly fewer blood products, with the greatest benefit seen
among those taking aspirin [20]. In a second double-
masked clinical trial, 55 patients who were taking aspirin
until the day before their CABG surgery were randomized
to receive a single dose of either 2 million KIU of apro-
tinin or placebo at the time of sternal skin closure [21].
Aprotinin recipients had a significantly lower hourly rate
(28 vs. 43 mL/h), and total volume (955 vs. 1570 mL), of
chest tube drainage, as well as a significant reduction in
the transfusion of PRBC (47% reduction), platelets (77%
reduction), FFP (88% reduction) and all blood products
(68% reduction) [21]. Thus, balanced against the known
cost, safety and availability of blood products [22] are the
potentially beneficial, but expensive, drugs like aprotinin,
and the less expensive agents, including tranexamic acid
[8]. Perhaps by restricting their use to patients at high risk
for major postoperative bleeding, including those taking
combined aspirin and clopidogrel, the cost of these drugs
can be better contained. Whether the use of intraoperative
monitoring of platelet function [23] can further enhance
this decision making process also remains unknown. A
randomized clinical trial, with a formal cost-effectiveness
analysis, might best address these points together.
Conclusions
The combined use of aspirin and clopidogrel shortly be-
fore CABG surgery may increase the associated risk of ex-
cess transfusion of blood products perioperatively. In lieu
of several study limitations herein, more valid data are
needed before the current findings are applied to clinical
practice.
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